阿利塞替布与研究者选择(选定单药)方案治疗复发或难治性外周T细胞淋巴瘤的随机III期研究
该开放标签、首次在此类患者中开展的随机III期试验纳入271例复发/难治性外周T细胞淋巴瘤成人患者,1:1随机接受阿利塞替布口服或研究者选择的单药 comparator(普拉曲沙、吉西他滨或罗米地辛)。因独立数据监查委员会认为阿利塞替布达到PFS优效性的概率低而提前终止入组。中心评估的总缓解率阿利塞替布组33% vs comparator组45%(OR 0.60;95%CI 0.33-1.08),中位PFS 115天 vs 104天(HR 0.87;95%CI 0.637-1.178),阿利塞替布未达统计学显著优效。
要点
- 阿利塞替布组总缓解率33% vs comparator组45%(OR 0.60;95%CI 0.33-1.08),差异未达统计学显著。
- 中位PFS阿利塞替布组115天 vs comparator组104天(HR 0.87;95%CI 0.637-1.178)。
- 两组2年总生存率均为35%,阿利塞替布未显著优于comparator。
核心结论
- 在复发/难治性外周T细胞淋巴瘤患者中,阿利塞替布未在统计学上显著优于comparator组。
研究设计与样本
- 开放标签、首次在此类患者中开展的随机III期试验,纳入复发/难治性外周T细胞淋巴瘤成人患者(既往≥1线治疗),1:1随机分配。
- 阿利塞替布组口服50 mg每日两次(第1-7天;21天周期);comparator组为研究者选择的单药:普拉曲沙30 mg/m2静脉(每周一次,共6周;7周周期),或吉西他滨1,000 mg/m2静脉、或罗米地辛14 mg/m2静脉(第1、8、15天;28天周期)。
- 2012年5月至2014年10月共随机分配271例患者(阿利塞替布组n=138;comparator组n=133)。
- 肿瘤组织(疾病亚型)和影像学由独立中心审查评估;主要终点为总缓解率和无进展生存期(PFS);计划两次中期分析和一次最终分析。
主要发现
- 因独立数据监查委员会认为在全入组下阿利塞替布达到PFS优效性的概率低,入组提前终止。
- 中心评估的总缓解率阿利塞替布组33% vs comparator组45%(OR 0.60;95%CI 0.33-1.08)。
- 中位PFS阿利塞替布组115天 vs comparator组104天(HR 0.87;95%CI 0.637-1.178)。
- 最常见不良事件为贫血(阿利塞替布组53% vs comparator组34%)和中性粒细胞减少(阿利塞替布组47% vs comparator组31%)。
- 导致研究药物停药的事件发生率阿利塞替布组9% vs comparator组14%;26例研究期间死亡中5例被认为与治疗相关(阿利塞替布组11例中3例;comparator组15例中2例);两组2年总生存率均为35%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 入组因独立数据监查委员会认为阿利塞替布达到PFS优效性的概率低而提前终止。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The aim of this open-label, first-in-setting, randomized phase III trial was to evaluate the efficacy of alisertib, an investigational Aurora A kinase inhibitor, in patients with relapsed/refractory peripheral T-cell lymphoma (PTCL). PATIENTS AND METHODS: Adult patients with relapsed/refractory PTCL-one or more prior therapy-were randomly assigned 1:1 to receive oral alisertib 50 mg two times per day (days 1 to 7; 21-day cycle) or investigator-selected single-agent comparator, including intravenous pralatrexate 30 mg/m2 (once per week for 6 weeks; 7-week cycle), or intravenous gemcitabine 1,000 mg/m2 or intravenous romidepsin 14 mg/m2 (days 1, 8, and 15; 28-day cycle). Tumor tissue (disease subtype) and imaging were assessed by independent central review. Primary outcomes were overall response rate and progression-free survival (PFS). Two interim analyses and one final analysis were planned. RESULTS: Between May 2012 and October 2014, 271 patients were randomly assigned (alisertib, n = 138; comparator, n = 133). Enrollment was stopped early on the recommendation of the independent data monitoring committee as a result of the low probability of alisertib achieving PFS superiority with full enrollment. Centrally assessed overall response rate was 33% for alisertib and 45% for the comparator arm (odds ratio, 0.60; 95% CI, 0.33 to 1.08). Median PFS was 115 days for alisertib and 104 days for the comparator arm (hazard ratio, 0.87; 95% CI, 0.637 to 1.178). The most common adverse events were anemia (53% of alisertib-treated patients v 34% of comparator-treated patients) and neutropenia (47% v 31%, respectively). A lower percentage of patients who received alisertib (9%) compared with the comparator (14%) experienced events that led to study drug discontinuation. Of 26 on-study deaths, five were considered treatment related (alisertib, n = 3 of 11; comparator, n = 2 of 15). Two-year overall survival was 35% for each arm. CONCLUSION: In patients with relapsed/refractory PTCL, alisertib was not statistically significantly superior to the comparator arm.
引用
- O'Connor OA, Özcan M, Jacobsen ED, et al. Randomized Phase III Study of Alisertib or Investigator's Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma. J Clin Oncol. 2019. PMID: 30707661. doi:10.1200/JCO.18.00899
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。